NASDAQ:ATXI
Avenue Therapeutics, Inc. Stock News
$4.40
+0.200 (+4.76%)
At Close: May 08, 2024
Avenue Therapeutics (ATXI) Gets a Buy Rating from Oppenheimer
04:32pm, Tuesday, 31'st Mar 2020
In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Avenue Therapeutics (ATXI), with a price target of $12.00. The
Avenue Therapeutics (ATXI) Gets a Buy Rating from Oppenheimer
04:32pm, Tuesday, 31'st Mar 2020
In a report released today,
Leland Gershell
from Oppenheimer maintained a
Buy
rating on Avenue Therapeutics (
ATXI
–
Research Report
), with a price target of
$12.00
. The company’s shares closed
Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), Phasebio Pharmaceuticals (PHAS)
11:29am, Tuesday, 31'st Mar 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics (AXSM), Phasebio Pharmaceuticals (PHAS)
Analysts’ Top Healthcare Picks: Axsome Therapeutics (AXSM), Phasebio Pharmaceuticals (PHAS)
11:29am, Tuesday, 31'st Mar 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Axsome Therapeutics
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights
11:30am, Monday, 30'th Mar 2020
NEW YORK, March 30, 2020 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.
The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut
01:30pm, Wednesday, 29'th Jan 2020
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 28) 10X Genomics Inc (NASDAQ: TXG ) Acceleron Pharma I
What we know about the woman who gave Laura Plummer Tramadol
05:39pm, Thursday, 31'st Jan 2019
Laura Plummer claims a 'friend' from work gave her the tablets
